Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,828
  • Shares Outstanding, K 34,384
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,880 K
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.78 +123.88%
on 04/01/19
3.15 -44.76%
on 04/22/19
+0.42 (+31.82%)
since 03/22/19
3-Month
0.78 +123.88%
on 04/01/19
3.15 -44.76%
on 04/22/19
+0.36 (+26.09%)
since 01/24/19
52-Week
0.78 +123.88%
on 04/01/19
3.15 -44.76%
on 04/22/19
-0.05 (-2.79%)
since 04/24/18

Most Recent Stories

More News
Biotech Brief: Optimistic Outlook Growing for Multi-billion Dollar Medical Device Industry

A recent industry article reported on an optimistic overview concerning the Medical Device Industry. It said: "The medical device industry should see a stand-out year in 2019, according to a Moody's report...

MHMNF : 54.5000 (unch)
IART : 51.34 (-3.17%)
BAX : 76.28 (-0.08%)
SOLY : 12.33 (-10.13%)
MBRX : 1.74 (+9.43%)
MBIO : 5.66 (-6.36%)
Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.74 (+9.43%)
Detailed Research: Economic Perspectives on America First Multifamily Investors, Pluralsight, Globus Medical, ContraFect, Moleculin Biotech, and RumbleON -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of America First Multifamily Investors,...

PS : 33.25 (-1.10%)
RMBL : 4.63 (+1.98%)
ATAX : 6.78 (unch)
GMED : 45.80 (+1.13%)
CFRX : 0.48 (unch)
MBRX : 1.74 (+9.43%)
Biotech Brief: FDA Fast Tracking Innovative Breakthrough Therapies For Cancer Patients

A recent headline from a report released by Friends of Cancer Research, made the following eye-opening statement: "ONE OF THE BIGGEST TREATMENT BREAKTHROUGHS IN THE PAST FIVE YEARS WASN'T A DRUG, BUT A...

WVE : 26.70 (-0.85%)
ZSAN : 3.96 (-0.25%)
BPTH : 18.58 (+2.94%)
PFE : 39.37 (-0.13%)
MBRX : 1.74 (+9.43%)
Moleculin Announces Significant Discovery in Lung Cancer Models

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.74 (+9.43%)
Why International Regulations on Clinical Trials can Actually Reduce Costs and Shorten Time to Market

Every business or industry strives to improve quality, reduce costs and improve their products time to market. This, surprisingly, is true for the biotechnology industry as well. Usually regulations increase...

TEVA : 15.00 (+0.60%)
OPK : 2.33 (-3.32%)
GERN : 1.87 (-2.60%)
GILD : 62.80 (-0.38%)
MBRX : 1.74 (+9.43%)
Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.74 (+9.43%)
Biotech Brief: Growing Number of Ongoing Clinical Trials for Leukemia (AML) Brings New Hope

In the last few years the number of clinical trials looking for new treatments for Leukemia (AML) has continued to grow. In 2017, a report from ManagedCare said that: "… There are over 400 phase 2 or...

CHRS : 14.50 (+2.26%)
CVM : 6.70 (+1.52%)
INO : 3.80 (-1.55%)
INSM : 30.93 (-2.09%)
MBRX : 1.74 (+9.43%)
Moleculin Announces Successful Expansion of its Leukemia Drug Program

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.74 (+9.43%)
Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.74 (+9.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade MBRX with:

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

2nd Resistance Point 2.34
1st Resistance Point 2.04
Last Price 1.74
1st Support Level 1.52
2nd Support Level 1.30

See More

52-Week High 3.15
Fibonacci 61.8% 2.24
Fibonacci 50% 1.96
Last Price 1.74
Fibonacci 38.2% 1.68
52-Week Low 0.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar